MedPath

Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Phase 2
Completed
Conditions
Nocturia Due to Nocturnal Polyuria
Interventions
Drug: Placebo
Registration Number
NCT03116191
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Brief Summary

The purpose of this trial is to demonstrate efficacy of SK-1404 against placebo for the treatment of subjects with nocturia due to nocturnal polyuria, during 4 weeks of treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
125
Inclusion Criteria
  • 5 > nocturnal voids ≥2
  • NPI >0.33
Exclusion Criteria
  • Polydipsia
  • Cardiac failure
  • Syndrome of inappropriate antidiuretic hormone secretion
  • Hyponatraemia
  • Uncontrolled diabetes mellitus
  • Uncontrolled hypertension
  • Moderate or severe over-active bladder (OAB)
  • Severe benign prostate hyperplasia (BPH)
  • Sleep apnoea
  • Interstitial cystitis
  • Stress urinary incontinence
  • Diabetes insipidus
  • Complication or a history of urological cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SK-1404 low doseSK-1404-
PlaceboPlacebo-
SK-1404 high doseSK-1404-
SK-1404 middle doseSK-1404-
Primary Outcome Measures
NameTimeMethod
Change from baseline in mean number of nocturnal voids4 weeks

Assessed by the voiding diary

Secondary Outcome Measures
NameTimeMethod
Change from base line in mean time to first awakening to void4 weeks

Assessed by the voiding diary

Change from base line in the score of Nocturia-Specific Quality-of-Life Questionnaire (N-QoL)4 weeks

Assessed by the voiding diary

Change from base line in mean nocturnal urine volume4 weeks

Assessed by the voiding diary

Change from base line in mean Nocturnal Polyuria Index (NPI)4 weeks

Assessed by the voiding diary

Trial Locations

Locations (1)

Investigational site (there may be other sites in this country)

🇯🇵

Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath